Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Here is What Hedge Funds Think About Clearside Biomedical, Inc. (CLSD)
04:53pm, Friday, 27'th Nov 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v
Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference
07:05am, Wednesday, 11'th Nov 2020
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript
11:11pm, Tuesday, 10'th Nov 2020
Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 10'th Nov 2020
- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® Ongoing b
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020
07:05am, Friday, 30'th Oct 2020
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical (CLSD) Enters Oversold Territory
05:24am, Tuesday, 27'th Oct 2020
Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Applied Genetic Technologies : AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator | MarketScreener
11:02am, Wednesday, 07'th Oct 2020Global Bionic Eye Market Size 2020 Research Findings, Market Growth Factors Analysis and Forecasts – 2026
03:48am, Monday, 28'th Sep 2020
Sep 27, 2020 (The Expresswire) --
2020 Bionic Eye Market :- Bionic Eye is an experimental visual device intended to restore functional vision in those...
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
10:45pm, Monday, 10'th Aug 2020
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the sto
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Monday, 10'th Aug 2020
\- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - \- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - \- Engaged New Contract Manufactu
\- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceuti
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
11:05am, Tuesday, 04'th Aug 2020
ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:31pm, Monday, 03'rd Aug 2020
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
